Cited by 337Monoclonal and Polyclonal Antibodies ResearchT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

Perez, Pilar, Hoffman, Robert W., Shaw, Stephen, Bluestone, Jeffrey A., Segal, David M.·1985·Nature

Open this paper in CoChat — free account

Abstract

The specificity of cytotoxic T lymphocytes (Tc) cells is conferred by an antigen-specific receptor, Ti, which in humans is physically associated with an invariant cell-surface glycoprotein, T3. Monoclonal antibodies specific for either T3 and Ti are able to elicit a variety of T-cell responses such as lymphokine production, mitogenesis and cytotoxicity. For example, human Tc cells lyse anti-T3-expressing hybridoma cells, but not cells of other specificity, presumably because anti-T3 on the hybridoma cells binds to T3 on the Tc cells and triggers lysis. Here, we have adapted approaches used in a different cytotoxic effector system, antibody-dependent cellular cytotoxicity (ADCC), to alter the specificity of Tc cell. Studies of ADCC showed that heteroaggregates containing anti-Fc receptor (Fc gamma R) antibody cross-linked to a second antibody bind to Fc gamma R on ADCC effectors and cause them to kill target cells bearing antigen recognized by the second antibody. The present studies use anti-T3-containing heteroaggregates to re-target human Tc cells to cells for which we have appropriate antibodies, including xenogeneic tumour cells and chicken erythrocytes. These results extend previous observations on the role of T3 in triggering cytotoxicity and suggest that effector cell re-targeting could be used for in vivo treatment of neoplasms and other pathogens that express distinctive surface antigens.

Integrity signals

Registry

Crossref · 10.1038/316354a0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.
Unkeless, J. C. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.3.580 · Cited by 1,271
OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties
Wauwe, J. P. V., DeMay, J., & Goossens, J. G. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.5.2359.a · Cited by 710
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
Wauwe, J. P. V., Mey, J. D., & Goossens, J. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.124.6.2708 · Cited by 582
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.
Meuer, S. C., Hodgdon, J. C., Hussey, R. E., Protentis, J. P., Schlossman, S. F., & Reinherz, E. L. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.3.988 · Cited by 423
The Major Histocompatibility Compex-Restricted Antigen Receptor on T Cells
HASKINS, K. M., Kappler, J. W., & Marrack, P. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000411 · Cited by 369
Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.
Shaw, S., Johnson, A. H., & Shearer, G. M. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.3.565 · Cited by 347
Self-citation
The Human T-Cell Receptor
Meuer, S. C., Acuto, O., Hercend, T., Schlossman, S. F., & Reinherz, E. L. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000323 · Cited by 233
Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies.
Landegren, U. D., Ramstedt, U., Axberg, I., Ullberg, M., Jondal, M., & Wigzell, H. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.5.1579 · Cited by 180
Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.
Kranz, D. M., Tonegawa, S., & Eisen, H. N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7922 · Cited by 177

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 2

Huffman, R. W., Bluestone, J. A., Leo, O. & Shaw, S. J. Immun. (in the press).
Sachs, D. H., Mayer, N. & Ozato, K. in Monoclonal Antibodies and T-Cell Hybridomas (eds Hammerling, G., Hammerling, U. & Kearny, J. F.) 95–101 (Eisevier, New York, 1981).

Sorted by citations

Items 101–200 of 336

Cyclic tetramolecular complexes of monoclonal antibodies: A new type of cross‐linking reagent
Lansdorp, P. M., Aalberse, R. C., Bos, R., Schutter, W. G., & Bruggen, E. F. J. V. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160615 · Cited by 43
Lectins and antibodies as tools for studying cellular interactions
Peacock, J. S., Colsky, A. S., & Pinto, V. B. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90145-l · Cited by 43
Glycosylation of the T-cell antigen-specific receptor and its potential role in lectin-mediated cytotoxicity.
Hubbard, S. C., Kranz, D. M., Longmore, G. D., Sitkovsky, M. V., & Eisen, H. N. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1852 · Cited by 42
Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
Schürch, C. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00152 · Cited by 42
An in-vitro model for tumor immunotherapy with antibody heteroconjugates
Jung, G., & Eberhard, H. J. M. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91304-7 · Cited by 41
Bispecific antibodies for the treatment of lymphomas: Promises and challenges
Schuster, S. J. (2021) · Hematological Oncology · doi:10.1002/hon.2858 · Cited by 43
Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.
Roosnek, E. E., & Lanzavecchia, A. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.1.297 · Cited by 40
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Rossi, D. L., Rossi, E. A., Cardillo, T. M., Goldenberg, D. M., & Chang, C. (2013) · mAbs · doi:10.4161/mabs.27385 · Cited by 39
Use of anti-receptor antibodies to focus T-cell activity
Staerz, U. D., & Bevan, M. J. (1986) · Immunology Today · doi:10.1016/0167-5699(86)90112-x · Cited by 39
Bispecific antibody: a tool for diagnosis and treatment of disease
Songsivilai, S., & Lachmann, P. J. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb08089.x · Cited by 39
Activation of mononuclear cells to be used for hybrid monoclonal antibody‐induced lysis of human ovarian carcinoma cells
Pupa, S. M., Canevari, S., Fontanelli, R., Ménard, S., Mezzanzanica, D., Lanzavecchia, A., & COLNAGHI, M. I. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420324 · Cited by 39
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias
Gupta, P., Goldenberg, D. M., Rossi, E. A., & Chang, C. (2010) · Blood · doi:10.1182/blood-2010-03-276857 · Cited by 38
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
del Bano, J., Chames, P., Baty, D., & Kerfélec, B. (2015) · Antibodies · doi:10.3390/antib5010001 · Cited by 39
Anti-CD3 × Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancer–Bearing Severe Combined Immunodeficient Beige Mice
Davol, P. A., Smith, J. A., KOUTTAB, N. M., Elfenbein, G. J., & Lum, L. G. (2004) · Clinical Prostate Cancer · doi:10.3816/cgc.2004.n.021 · Cited by 38
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
Yang, Y., Yang, Z., & Yang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686031 · Cited by 38
Antigen-receptor interaction requirement for conjugate formation and lethal-hit triggering by cytotoxic T lymphocytes can be bypassed by protein kinase C activators and Ca2+ ionophores.
Berrebi, G. A., Takayama, H., & Sitkovsky, M. V. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1364 · Cited by 37
RECRUIT-TandAbs ® : Harnessing the Immune System to Kill Cancer Cells
McAleese, F., & Eser, M. (2012) · Future Oncology · doi:10.2217/fon.12.54 · Cited by 36
Induction of cytotoxicity in human T cells coated with anti-glioma × anti-CD3 bispecific antibody against human glioma cells
Nitta, T., Sato, K., Okumura, K., & Ishii, S. (1990) · Journal of neurosurgery · doi:10.3171/jns.1990.72.3.0476 · Cited by 36
Cell–Cell Interactions
BOLHUIS, R. L. H., Gravekamp, C., & van de Griend, R. J. (1986) · Clinics in Immunology and Allergy · doi:10.1016/s0260-4639(22)00164-5 · Cited by 36
A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells
Kaneko, T., FUSAUCHI, Y., Kakui, Y., Masuda, M., Akahoshi, M., Teramura, M., Motoji, T., Okumura, K., Mizoguchi, H., & Oshimi, K. (1993) · Blood · doi:10.1182/blood.v81.5.1333.1333 · Cited by 35
Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
Gilliland, L. K., Clark, M., & Waldmann, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7719 · Cited by 35
The cytolytic T lymphocyte and its mode of action
Berke, G. (1989) · Immunology Letters · doi:10.1016/0165-2478(89)90075-8 · Cited by 35
Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido, M. A., Valdayo, M. J., Winkler, D. F., Titus, J. A., Hecht, T. T., Perez, P., Segal, D. M., & Wunderlich, J. R. (1990) · PubMed · Cited by 35
Self-citation
Monoclonal antibodies for imaging and therapy
Epenetos, A., & Kosmas, C. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.32 · Cited by 35
Chemically Programmed Bispecific Antibodies in Diabody Format
Walseng, E., Nelson, C. G., Qi, J., Nanna, A. R., Roush, W. R., Goswami, R. K., Sinha, S. C., Burke, T. R., & Rader, C. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.745588 · Cited by 34
Immunotherapeutic progress and application of bispecific antibody in cancer
Kang, J., Sun, T., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020003 · Cited by 37
Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity
Mueller, E. A., Hamprecht, K., & Anderer, F. A. (1989) · Immunopharmacology · doi:10.1016/0162-3109(89)90003-9 · Cited by 33
Bispecific monoclonal antibodies directed to CD16 and to a tumor‐associated antigen induce target‐cell lysis by resting NK cells and by a subset of NK clones
Ferrini, S., Prigione, I., Miotti, S., Ciccone, E., Cantoni, C., Chen, Q., COLNAGHI, M. I., & Moretta, L. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480213 · Cited by 33
Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site
List, T., & Neri, D. (2012) · mAbs · doi:10.4161/mabs.22271 · Cited by 32
Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
Eckert, F., Gaipl, U. S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2016.12.006 · Cited by 32
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
Register, A. C., Tarighat, S. S., & Lee, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105350 · Cited by 32
Glofitamab CD20-TCB bispecific antibody
Minson, A. G., & Dickinson, M. J. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1953016 · Cited by 32
Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo, I. G., Gerçel-Taylor, Ç., Kitson, J., & Weiner, L. M. (1990) · PubMed · Cited by 32
Identification and characterization of SKAT-2, a novel Th2-specific zinc finger gene
Blanchard, A. D., Page, K. R., Watkin, H., Hayward, P., Wong, T., Bartholomew, M. A., Quint, D. J., Daly, M. G., Garcia-Lopez, J., & CHAMPION, B. R. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200011)30:11 · Cited by 9
CD30‐antigen‐specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphoma
Pohl, C., Denfeld, R. W., Renner, C., Jung, W. E., Bohlen, H., Şahin, U., Hombach, A. A., van Lier, R. A. W., Schwonzen, M., Diehl, V., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540517 · Cited by 32
[Pharmacokinetics and metabolism of trazodone in man (author's transl)].
Jauch, R., Kopitar, Z., Prox, A., & Zimmer, A. (1976) · PubMed · Cited by 31
T cell targeting in cancer therapy
Bolhuis, R. L. H., Sturm, E., & Braakman, E. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741317 · Cited by 31
CD33 directed bispecific antibodies in acute myeloid leukemia
Clark, M. C., & Stein, A. S. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101224 · Cited by 30
Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19)
Haagen, I.-A., van de Griend, R. J., Clark, M., Geerars, A., Bast, B. J. E. G., & de Gast, B. C. (1992) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1992.tb05853.x · Cited by 30
Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments
Schott, M. E., Frazier, K., Pollock, D. K., & Verbanac, K. M. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00020a008 · Cited by 30
Strategies for the management of recurrent and advanced urologic cancers. Quality of life
Herr, H. W. (1987) · Cancer · doi:10.1002/1097-0142(19870801)60:3+ · Cited by 15
Monoclonal Antibodies: State of the Art
Bander, N. H. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)44154-1 · Cited by 30
Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes
Ogg, G. S., Dunbar, P. R., Cerundolo, V., McMichael, A. J., Lemoine, N. R., & Savage, P. M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1042 · Cited by 29
A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL
Jost, C. R., Titus, J. A., Kurucz, I., & Segal, D. M. (1996) · Molecular Immunology · doi:10.1016/0161-5890(95)00087-9 · Cited by 29
Self-citation
Human C‐ERBB‐2 proto‐oncogene product as a target for bispecific‐antibody‐directed adoptive tumor immunotherapy
Nishimura, T., Nakamura, Y., Tsukamoto, H., Takeuchi, Y., Tokuda, Y., Iwasawa, M., Yamamoto, T. S., Masuko, T., Hashimoto, Y., & Habu, S. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500523 · Cited by 29
Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., & Slavin, S. (2005) · Blood · doi:10.1182/blood-2005-07-2738 · Cited by 28
The LFA‐1/ICAM cell adhesion pathway is involved in tumor‐cell lysis mediated by bispecific monoclonal‐antibody‐targeted T lymphocytes
Ferrini, S., Sforzini, S., Cambiaggi, A., Poggi, A. D., Meazza, R., Canevari, S., COLNAGHI, M. I., & Moretta, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560616 · Cited by 28
Bispecific antibodies for targeted cellular cytotoxicity
Fanger, M. W. (1991) · Trends in biotechnology · doi:10.1016/0167-7799(91)90129-6 · Cited by 28
Bispecific antibodies for treatment of cancer in experimental animal models and man
Kroesen, B. J., Helfrich, W., Molema, G., & de Leij, L. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00096-3 · Cited by 27
In vivo localization of a bispecific antibody which targets human t lymphocytes to lyse human colon cancer cells
Barr, I., Miescher, S., Fliedner, V. E. V., Buchegger, F., Barras, C., Lanzavecchia, A., Mach, J., & Carrel, S. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430327 · Cited by 27
Current strategies of antibody‐based treatment in Hodgkin's disease
Schnell, R., Borchmann, P., Schulz, H., & Engert, A. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.57 · Cited by 27
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy
Mehrabadi, A. Z., Tat, M., Alvanegh, A. G., Roozbahani, F., & Ghaleh, H. E. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343378 · Cited by 29
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development
Chen, T.-H. T. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2098674 · Cited by 28
Optically Induced Cell Fusion Using Bispecific Nanoparticles
Yeheskely‐Hayon, D., Minai, L., Golan, L., Dann, E. J., & Yelin, D. (2013) · Small · doi:10.1002/smll.201300696 · Cited by 26
The use of chimeric human Fcε receptor I to redirect cytotoxic T lymphocytes to tumors
Kershaw, M. H., Darcy, P. K., Trapani, J. A., & Smyth, M. J. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.6.721 · Cited by 26
Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma
Haagen, I.-A., Geerars, A., de Lau, W., Clark, M., van de Griend, R. J., Bast, B. J. E. G., & de Gast, B. C. (1994) · Blood · doi:10.1182/blood.v84.2.556.556 · Cited by 26
Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
Aureli, A., Marziani, B., Sconocchia, T., Principe, M. I. D., Buzzatti, E., Pasqualone, G., Venditti, A., & Sconocchia, G. (2021) · Cancers · doi:10.3390/cancers13246246 · Cited by 25
The current status of immunotherapy in peritoneal carcinomatosis
Ströhlein, M. A., Heiss, M. M., & Jauch, K. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1224666 · Cited by 25
The Generation of Cytotoxic T Lymphocytes Against Acetaldehyde‐modified Syngeneic Cell
Terabayashi, H., & Kolber, M. A. (1990) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1990.tb01833.x · Cited by 25
Retargeting T cells and immune effector cells with bispecific antibodies
Lum, L. G., & Davol, P. A. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22013-0 · Cited by 25
Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
Penna, C., Dean, P. A., & Nelson, H. D. (1994) · PubMed · Cited by 25
Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts
Khaw, B., Gada, K. S., Patil, V., Panwar, R., Mandapati, S., Hatefi, A., Majewski, S., & Weisenberger, A. G. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2738-2 · Cited by 24
Alkaline cation-exchange chromatography for the reduction of aggregate and a mis-formed disulfide variant in a bispecific antibody purification process
Hall, T., Wilson, J. J., Brownlee, T. J., Swartling, J. R., Langan, S. E., & Lambooy, P. K. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.11.002 · Cited by 24
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Hybrid antibody‐mediated lysis of virus‐infected cells
Staerz, U. D., Yewdell, J. W., & Bevan, M. J. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170422 · Cited by 24
Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL
Qin, H. (2004) · International Immunology · doi:10.1093/intimm/dxh167 · Cited by 23
Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies
Kodama, H., Suzuki, M., Katayose, Y., Shinoda, M., Sakurai, N., Takemura, S.-I., Yoshida, H., Saeki, H., Asano, R., Ichiyama, M., et al. (2002) · Immunology Letters · doi:10.1016/s0165-2478(01)00343-1 · Cited by 23
Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies
Barr, I., MacDonald, H. R., Buchegger, F., & Fliedner, V. E. V. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910400323 · Cited by 23
Targeted cytotoxic cells as a novel form of cancer immunotherapy
Segal, D. M., Garrido, M. A., Pérez, P., Titus, J. A., Winkler, D. A., Ring, D. B., Kaubisch, A., & Wunderlich, J. R. (1988) · Molecular Immunology · doi:10.1016/0161-5890(88)90144-7 · Cited by 23
Self-citation
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 22
Mechanisms Responsible for Granzyme B–Independent Cytotoxicity
Shresta, S., Russell, J. H., & Ley, T. J. (1997) · Blood · doi:10.1182/blood.v89.11.4085 · Cited by 22
Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments.
Robert, B., Guillaume, P., Luescher, I. F., Doucey, M., Cerottini, J., Romero, P. J., & Mach, J. (2001) · PubMed · Cited by 22
MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
Li, H., Huang, C., Zhang, Z., Feng, Y., Wang, Z., Tang, X., Zhong, K., Hu, Y., Guo, G. F., Zhou, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01527 · Cited by 19
Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer
Vaidya, T. R., Straubinger, R. M., & Ait‐Oudhia, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2365-x · Cited by 21
Hybrid Antibodies in Cancer Diagnosis and Therapy
Ménard, S., Canevari, S., & COLNAGHI, M. I. (1989) · The International Journal of Biological Markers · doi:10.1177/172460088900400301 · Cited by 21
Multidrug resistance in ovarian cancer
Fojo, A. T., Hamilton, T. C., Young, R. C., & Ozols, R. F. (1987) · Cancer · doi:10.1002/1097-0142(19901015)60:8+ · Cited by 93
Current Trends and Innovative Approaches in Cancer Immunotherapy
Kim, J.-C., Maharjan, R., & Park, J. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02883-x · Cited by 25
T Cell Engineering
Pircher, M., Schirrmann, T., & Petrausch, U. (2015) · Progress in tumor research · doi:10.1159/000437180 · Cited by 21
EGF Family Receptors and Their Ligands in Human Cancer
Tang, C. K., & Lippman, M. E. (1998) · Elsevier eBooks · doi:10.1016/b978-012312411-1/50006-8 · Cited by 20
Immunotherapy of metastatic renal cell cancer
Goey, S. H., Verweij, J., & Stoter, G. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010790 · Cited by 20
A new class of antigen-specific killer cells
Yang, A., & Chen, S. Y. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-46 · Cited by 19
Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody
Oshimi, K., Takumi, S. E. T. O., Oshimi, Y., Masuda, M., Okumura, K., & Mizoguchi, H. (1991) · Blood · doi:10.1182/blood.v77.5.1044.1044 · Cited by 19
Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone
Tian, Z., Yu, C., Zhang, W., Wu, K., Wang, C., Gupta, R., Xu, Z., Wu, L., Chen, Y., Zhang, X. H.-F., et al. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01024 · Cited by 18
A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
Liang, J., Zhang, H., Huang, Y., Fan, L., Li, F., Li, M., Yan, Y., Zhang, J., Li, Z., & Yang, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330637 · Cited by 18
In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
Donda, A., Cesson, V., Mach, J., Corradin, G., Primus, F. J., & Robert, B. (2003) · PubMed · Cited by 18
Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes
Möller, S. A., & Reisfeld, R. A. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01744939 · Cited by 18
The Use of Gene‐Modified Tumor‐Infiltrating Lymphocytes for Cancer Therapy
Hwu, P., & Rosenberg, S. A. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21712.x · Cited by 17
Use of bispecific antibodies in the therapy of tumors
Fanger, M. W., Morganelli, P. M., & Guyre, P. M. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3076-3_10 · Cited by 17
The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells.
Zalman, L. S., Martin, D. E., Jung, G., & Müller‐Eberhard, H. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2426 · Cited by 17
The way ahead for vaccines and vaccination: symposium summary
Mitchell, G. F. (1988) · Vaccine · doi:10.1016/s0264-410x(88)80029-x · Cited by 17
The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy
Clark, M., Gilliland, L. K., & Waldmann, H. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410706 · Cited by 17
Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
Noori, M., Yazdanpanah, N., & Rezaei, N. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03045-y · Cited by 16
Performance of CD3xCD19 Bispecific Monoclonal Antibodies in B Cell Malignancy
Haagen, I.-A. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509112195 · Cited by 16
Targeting of Anti-Tumor Responses with Bispecific Antibodies
Segal, D. M., Qian, J., Mezzanzanica, D., Garrido, M. A., Titus, J. A., Andrew, S. M., George, A. J. T., Jost, C. R., Pérez, P., & Wunderlich, J. R. (1992) · Immunobiology · doi:10.1016/s0171-2985(11)80655-8 · Cited by 16
Self-citation
Identification of high-affinity anti-CD16A allotype-independent human antibody domains
Li, W., Yang, H., & Dimitrov, D. S. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.10.001 · Cited by 15
Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic
Mezzanzanica, D., Canevari, S., & COLNAGHI, M. I. (1992) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02591636 · Cited by 15
Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: A possible approach to the immunotherapy of human tumors
Lotze, M. T., Roberts, K., Custer, M. C., Segal, D. A., & Rosenberg, S. A. (1987) · Journal of Surgical Research · doi:10.1016/0022-4804(87)90036-9 · Cited by 15
Self-citation
Investigational treatment strategies in glioblastoma: progress made and barriers to success
Nelson, T. A., & Dietrich, J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267982 · Cited by 15
Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody × MHC/Viral Peptide Conjugates
Cesson, V., Stirnemann, K., Robert, B., Luescher, I. F., Filleron, T., Corradin, G., Mach, J., & Donda, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1862 · Cited by 14

Authors: Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M.
Affiliations: National Institutes of Health (US)
ORCID: Shaw, Stephen
Bluestone, Jeffrey A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1985-07
Volume: 316
Issue: 6026
Pages: 354-356
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/316354a0
OpenAlex: W2065272367
Cited by: 337
References: 23
Citations by year: 2026: 4 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 6 · 2016: 6 · 2015: 4 · 2014: 11 · 2013: 6 · 2012: 6
FWCI: 22.63
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: cytotoxic T lymphocytes, T cell receptor, antibody-dependent cellular cytotoxicity, heteroaggregates, T cell specificity, chicken erythrocytes, T cell cytotoxicity
MeSH terms: Animals, Antibodies, Antibodies, Monoclonal, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Antigens, Surface, Clone Cells, Glycoproteins, Histocompatibility Antigens, Humans, Receptors, Antigen, T-Cell, T-Lymphocytes, Cytotoxic, CD3 Complex, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks